These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
185 related articles for article (PubMed ID: 34986328)
1. COVID-19 mRNA booster vaccines elicit strong protection against SARS-CoV-2 Omicron variant in patients with cancer. Zeng C; Evans JP; Chakravarthy K; Qu P; Reisinger S; Song NJ; Rubinstein MP; Shields PG; Li Z; Liu SL Cancer Cell; 2022 Feb; 40(2):117-119. PubMed ID: 34986328 [No Abstract] [Full Text] [Related]
2. mRNA-1273 and BNT162b2 mRNA vaccines have reduced neutralizing activity against the SARS-CoV-2 omicron variant. Edara VV; Manning KE; Ellis M; Lai L; Moore KM; Foster SL; Floyd K; Davis-Gardner ME; Mantus G; Nyhoff LE; Bechnak S; Alaaeddine G; Naji A; Samaha H; Lee M; Bristow L; Gagne M; Roberts-Torres J; Henry AR; Godbole S; Grakoui A; Saxton M; Piantadosi A; Waggoner JJ; Douek DC; Rouphael N; Wrammert J; Suthar MS Cell Rep Med; 2022 Feb; 3(2):100529. PubMed ID: 35233550 [TBL] [Abstract][Full Text] [Related]
3. Standardised neutralising antibody assays are needed for evaluating COVID-19 vaccines. Wang Y EBioMedicine; 2021 Nov; 73():103677. PubMed ID: 34742128 [No Abstract] [Full Text] [Related]
4. Correlation of vaccine-elicited antibody levels and neutralizing activities against SARS-CoV-2 and its variants. Liu J; Bodnar BH; Padhiar NH; Khan AI; Meng F; Saribas S; Wang P; Wang X; McCluskey E; Shah S; Zhao H; Luo JJ; Hu WH; Ho WZ Clin Transl Med; 2021 Dec; 11(12):e644. PubMed ID: 34923762 [No Abstract] [Full Text] [Related]
5. First SARS-CoV-2 Omicron infection as an effective immune booster among mRNA vaccinated individuals: final results from the first phase of the PRIBIVAC randomised clinical trial. Poh XY; Lee IR; Tan CW; Chavatte JM; Fong SW; Goh YS; Rouers A; Wong N; Torres-Ruesta A; Mah SYY; Yeoh AYY; Gandhi M; Rahman N; Chin YQ; Lim JJ; Yoong TJK; Rao S; Chia PY; Ong SWX; Lee TH; Sadarangani SP; Lin RJH; Lim DRX; Chia W; Renia L; Ren EC; Lin RTP; Lye DC; Wang LF; Ng LFP; Young BE EBioMedicine; 2024 Sep; 107():105275. PubMed ID: 39137572 [TBL] [Abstract][Full Text] [Related]
6. Immunogenicity and safety of COVID-19 booster vaccination: A population-based clinical trial to identify the best vaccination strategy. Sieghart D; Hana CA; Dürrschmid C; Heinz LX; Haslacher H; Zlesak M; Piccini G; Manenti A; Montomoli E; Jorda A; Fedrizzi C; Hasenoehrl T; Zdravkovic A; Anderle K; Wiedermann U; Drapalik S; Steinbrecher H; Bergmann F; Firbas C; Jordakieva G; Wagner B; Leonardi M; Pierleoni G; Ballini M; Benincasa L; Marchi S; Trombetta C; Perkmann T; Crevenna R; Zeitlinger M; Bonelli M; Aletaha D; Radner H J Clin Virol; 2024 Aug; 173():105661. PubMed ID: 38503118 [TBL] [Abstract][Full Text] [Related]
7. Distinct T cell responsiveness to different COVID-19 vaccines and cross-reactivity to SARS-CoV-2 variants with age and CMV status. Brummelman J; Suárez-Hernández S; de Rond L; Bogaard-van Maurik M; Molenaar P; van Wijlen E; Oomen D; Beckers L; Rots NY; van Beek J; Nicolaie MA; van Els CACM; Boer MC; Kaaijk P; Buisman AM; de Wit J Front Immunol; 2024; 15():1392477. PubMed ID: 38774878 [TBL] [Abstract][Full Text] [Related]
8. Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron. Carreño JM; Alshammary H; Tcheou J; Singh G; Raskin AJ; Kawabata H; Sominsky LA; Clark JJ; Adelsberg DC; Bielak DA; Gonzalez-Reiche AS; Dambrauskas N; Vigdorovich V; ; Srivastava K; Sather DN; Sordillo EM; Bajic G; van Bakel H; Simon V; Krammer F Nature; 2022 Feb; 602(7898):682-688. PubMed ID: 35016197 [TBL] [Abstract][Full Text] [Related]
9. Follow-Up and Comparative Assessment of SARS-CoV-2 IgA, IgG, Neutralizing, and Total Antibody Responses After BNT162b2 or mRNA-1273 Heterologous Booster Vaccination. Younes S; Nicolai E; Pieri M; Bernardini S; Daas HI; Al-Sadeq DW; Younes N; Shurrab FM; Nizamuddin PB; Humaira F; Al-Dewik N; Yassine HM; Abu-Raddad LJ; Ismail A; Nasrallah GK Influenza Other Respir Viruses; 2024 May; 18(5):e13290. PubMed ID: 38706402 [TBL] [Abstract][Full Text] [Related]
10. Immunogenicity of COVID-19 booster vaccination in IEI patients and their one year clinical follow-up after start of the COVID-19 vaccination program. van Leeuwen LPM; Grobben M; GeurtsvanKessel CH; Ellerbroek PM; de Bree GJ; Potjewijd J; Rutgers A; Jolink H; van de Veerdonk FL; van Gils MJ; de Vries RD; Dalm VASH; Front Immunol; 2024; 15():1390022. PubMed ID: 38698851 [TBL] [Abstract][Full Text] [Related]
11. Assessment of the neutralizing antibody response in Omicron breakthrough cases in healthcare workers who received the homologous booster of Moderna mRNA-1273. Gillot C; Tré-Hardy M; Cupaiolo R; Blairon L; Wilmet A; Beukinga I; Dogné JM; Douxfils J; Favresse J Virology; 2024 Jul; 595():110082. PubMed ID: 38636363 [TBL] [Abstract][Full Text] [Related]
12. Imprinting of serum neutralizing antibodies by Wuhan-1 mRNA vaccines. Liang CY; Raju S; Liu Z; Li Y; Asthagiri Arunkumar G; Case JB; Scheaffer SM; Zost SJ; Acreman CM; Gagne M; Andrew SF; Carvalho Dos Anjos DC; Foulds KE; McLellan JS; Crowe JE; Douek DC; Whelan SPJ; Elbashir SM; Edwards DK; Diamond MS Nature; 2024 Jun; 630(8018):950-960. PubMed ID: 38749479 [TBL] [Abstract][Full Text] [Related]
13. Ipsilateral or contralateral boosting of mice with mRNA vaccines confers equivalent immunity and protection against a SARS-CoV-2 Omicron strain. Ying B; Liang C-Y; Desai P; Scheaffer SM; Elbashir SM; Edwards DK; Thackray LB; Diamond MS J Virol; 2024 Sep; 98(9):e0057424. PubMed ID: 39194250 [TBL] [Abstract][Full Text] [Related]
14. Establishment of human post-vaccination SARS-CoV-2 standard reference sera. Xiang J; Katz L; Winokur PL; Chaudhary A; Digmann B; Bradford R; Rashid S; Ghosh S; Robertson A; Menetski J; Xu M; Gao P; Chen CZ; Lee T; Poelaert B; Eastman RT; Hall MD; Stapleton JT J Immunol Methods; 2024 Jul; 530():113698. PubMed ID: 38823574 [TBL] [Abstract][Full Text] [Related]
17. Neutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA vaccine-elicited human sera. Muik A; Lui BG; Wallisch AK; Bacher M; Mühl J; Reinholz J; Ozhelvaci O; Beckmann N; Güimil Garcia RC; Poran A; Shpyro S; Finlayson A; Cai H; Yang Q; Swanson KA; Türeci Ö; Şahin U Science; 2022 Feb; 375(6581):678-680. PubMed ID: 35040667 [TBL] [Abstract][Full Text] [Related]
18. Immunogenicity of mRNA vs. BBV152 vaccine boosters against Omicron subvariants: Final results from Phase B of the PRIBIVAC study, a randomized clinical trial. Poh XY; Torres-Ruesta A; Yoong T; Wong N; Tan CW; Rouers A; Chavatte JM; Goh YS; Rao S; Chia PY; Ong SWX; Lee TH; Sadarangani SP; Lin RJH; Neo V; Kam IKJ; Huang Y; Hor PX; Loh CY; ; Yeoh AY; Lim DRX; Chia W; Ren EC; Lin RTP; Fong SW; Renia L; Lye DC; Wang LF; Ng LFP; Young BE Vaccine; 2024 Nov; 42(25):126275. PubMed ID: 39241318 [TBL] [Abstract][Full Text] [Related]